Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Aprea Therapeutics Inc is a biotechnology business based in the US. Aprea Therapeutics shares (APRE) are listed on the NASDAQ and all prices are listed in US Dollars. Aprea Therapeutics employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$5.14|
|52-week range||$3.17 - $30.99|
|50-day moving average||$4.88|
|200-day moving average||$4.64|
|Wall St. target price||$4.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.25|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-4.64%|
|1 month (2021-09-17)||1.58%|
|3 months (2021-07-16)||1.98%|
|6 months (2021-04-16)||10.54%|
|1 year (2020-10-16)||-78.62%|
|2 years (2019-10-17)||-74.90%|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-31.29%|
|Return on equity TTM||-59.14%|
|Market capitalisation||$108.9 million|
TTM: trailing 12 months
There are currently 805,279 Aprea Therapeutics shares held short by investors – that's known as Aprea Therapeutics's "short interest". This figure is 171% up from 297,182 last month.
There are a few different ways that this level of interest in shorting Aprea Therapeutics shares can be evaluated.
Aprea Therapeutics's "short interest ratio" (SIR) is the quantity of Aprea Therapeutics shares currently shorted divided by the average quantity of Aprea Therapeutics shares traded daily (recently around 2.2 million). Aprea Therapeutics's SIR currently stands at 0.36. In other words for every 100,000 Aprea Therapeutics shares traded daily on the market, roughly 360 shares are currently held short.
However Aprea Therapeutics's short interest can also be evaluated against the total number of Aprea Therapeutics shares, or, against the total number of tradable Aprea Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aprea Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aprea Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0521% of the tradable shares (for every 100,000 tradable Aprea Therapeutics shares, roughly 52 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aprea Therapeutics.
Find out more about how you can short Aprea Therapeutics stock.
We're not expecting Aprea Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aprea Therapeutics's shares have ranged in value from as little as $3.17 up to $30.991. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aprea Therapeutics's is -0.1197. This would suggest that Aprea Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aprea Therapeutics has bucked the trend.
Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts. .
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.